Impact of MenACWY Vaccine Program on Disease Incidence Examined
According to a review published in Clinical Infectious Diseases, the incidence of meningococcal disease in the United States has decreased across all age groups and predominant serogroups.
To better understand trends in meningococcal disease following the introduction of the meningococcal conjugate vaccine, MenACWY, researchers calculated incidence rates and case-fatality ratios stratified by age and serogroup during 2006–2015 using data from the National Notifiable Diseases Surveillance System (NNDSS); the vaccine was recommended for routine use in adolescents 11 to 18 years of age in 2005. They also evaluated 20-year trends (1996–2015) in age- and race-standardized incidence using data from the Active Bacterial Core surveillance (ABCs).
The data showed 7,924 cases of meningococcal disease were reported to NNDSS during 2006–2015, averaging to an annual incidence of 0.26 cases per 100,000 population. Of these total cases, 14.9% were fatal.
The majority of cases were serogroup B (35.8%; n=2,290), followed by serogroup Y (28.5%; n=1,827), serogroup C (22.8%; n=1,457), serogroup W (6.8%; n=436), and other serogroups (6.1%; n=392). The authors noted a 76% decline in the incidence of serogroups A, C, W, and Y among individuals aged 11–20 years from 2006–2010 to 2011–2015 (P<0.0001).
"Reductions in the incidence of meningococcal disease due to serogroups A, C, W, and Y among adolescents suggest an impact of the MenACWY vaccine program in this age group," concluded lead author Jessica R. MacNeil.
For more information visit academic.oup.com.